Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) is set to announce its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). The firm had revenue of $10.09 million during the quarter, compared to analyst estimates of $50.00 million. During the same period in the previous year, the company posted ($0.23) EPS. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Autolus Therapeutics Trading Down 8.2 %
NASDAQ AUTL opened at $3.90 on Wednesday. The stock has a market cap of $1.04 billion, a PE ratio of -3.25 and a beta of 2.11. Autolus Therapeutics has a twelve month low of $2.01 and a twelve month high of $7.45. The stock has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $4.92.
Analyst Ratings Changes
Check Out Our Latest Research Report on AUTL
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
- Five stocks we like better than Autolus Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What is the Nikkei 225 index?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Why Invest in High-Yield Dividend Stocks?
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.